195 related articles for article (PubMed ID: 11504076)
1. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation.
Reske SN; Bunjes D; Buchmann I; Seitz U; Glatting G; Neumaier B; Kotzerke J; Buck A; Martin H; Döhner H; Bergmann L
Eur J Nucl Med; 2001 Jul; 28(7):807-15. PubMed ID: 11504076
[TBL] [Abstract][Full Text] [Related]
2. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
[TBL] [Abstract][Full Text] [Related]
3. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia.
Bunjes D
Leuk Lymphoma; 2002 Nov; 43(11):2125-31. PubMed ID: 12533037
[TBL] [Abstract][Full Text] [Related]
4. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Ringhoffer M; Blumstein N; Neumaier B; Glatting G; von Harsdorf S; Buchmann I; Wiesneth M; Kotzerke J; Zenz T; Buck AK; Schauwecker P; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
Br J Haematol; 2005 Aug; 130(4):604-13. PubMed ID: 16098076
[TBL] [Abstract][Full Text] [Related]
5. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
Bunjes D; Buchmann I; Duncker C; Seitz U; Kotzerke J; Wiesneth M; Dohr D; Stefanic M; Buck A; Harsdorf SV; Glatting G; Grimminger W; Karakas T; Munzert G; Döhner H; Bergmann L; Reske SN
Blood; 2001 Aug; 98(3):565-72. PubMed ID: 11468151
[TBL] [Abstract][Full Text] [Related]
6. Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study.
Zenz T; Glatting G; Schlenk RF; Buchmann I; Döhner H; Reske SN; Bunjes D
Haematologica; 2006 Feb; 91(2):285-6. PubMed ID: 16461327
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
Kotzerke J; Glatting G; Seitz U; Rentschler M; Neumaier B; Bunjes D; Duncker C; Dohr D; Bergmann L; Reske SN
J Nucl Med; 2000 Mar; 41(3):531-7. PubMed ID: 10716329
[TBL] [Abstract][Full Text] [Related]
8. 188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation.
Lauter A; Strumpf A; Platzbecker U; Schetelig J; Wermke M; Radke J; Kiani A; Wunderlich G; Thiede C; Ehninger G; Kotzerke J; Bornhäuser M
Br J Haematol; 2010 Mar; 148(6):910-7. PubMed ID: 19995390
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.
Zenz T; Schlenk RF; Glatting G; Neumaier B; Blumstein N; Buchmann I; von Harsdorf S; Ringhoffer M; Wiesneth M; Keller F; Kotzerke J; Röttinger E; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
J Nucl Med; 2006 Feb; 47(2):278-86. PubMed ID: 16455634
[TBL] [Abstract][Full Text] [Related]
10. Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Schneider S; Strumpf A; Schetelig J; Wunderlich G; Ehninger G; Kotzerke J; Bornhäuser M
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1754-60. PubMed ID: 26001695
[TBL] [Abstract][Full Text] [Related]
11. [Myeloablative radioimmunotherapy with 188Re-CD66mAb before stem cell transplantation. No increase of proinflammatory cytokine levels of TNF-alpha].
Mutschler J; Steinbach G; Bunjes D; Reske SN; Buchmann I
Nuklearmedizin; 2009; 48(1):30-6. PubMed ID: 19212609
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia.
Koenecke C; Hofmann M; Bolte O; Gielow P; Dammann E; Stadler M; Franzke A; Boerner AR; Eder M; Ganser A; Knapp W; Hertenstein B
Int J Hematol; 2008 May; 87(4):414-421. PubMed ID: 18415659
[TBL] [Abstract][Full Text] [Related]
13. Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Kim JH; Stein A; Tsai N; Schultheiss TE; Palmer J; Liu A; Rosenthal J; Forman SJ; Wong JY
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):75-81. PubMed ID: 24725691
[TBL] [Abstract][Full Text] [Related]
14. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation.
Wong JY; Liu A; Schultheiss T; Popplewell L; Stein A; Rosenthal J; Essensten M; Forman S; Somlo G
Biol Blood Marrow Transplant; 2006 Mar; 12(3):306-15. PubMed ID: 16503500
[TBL] [Abstract][Full Text] [Related]
15. Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.
Stein A; Palmer J; Tsai NC; Al Malki MM; Aldoss I; Ali H; Aribi A; Farol L; Karanes C; Khaled S; Liu A; O'Donnell M; Parker P; Pawlowska A; Pullarkat V; Radany E; Rosenthal J; Sahebi F; Salhotra A; Sanchez JF; Schultheiss T; Spielberger R; Thomas SH; Snyder D; Nakamura R; Marcucci G; Forman SJ; Wong J
Biol Blood Marrow Transplant; 2017 Apr; 23(4):618-624. PubMed ID: 28087456
[TBL] [Abstract][Full Text] [Related]
16. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation.
Matthews DC; Appelbaum FR; Eary JF; Fisher DR; Durack LD; Bush SA; Hui TE; Martin PJ; Mitchell D; Press OW
Blood; 1995 Feb; 85(4):1122-31. PubMed ID: 7849300
[TBL] [Abstract][Full Text] [Related]
17. Re-186 HEDP conditioning therapy in patients with advanced acute lymphoblastic leukemia before allogeneic bone marrow transplantation.
Döbert N; Martin H; Kranert WT; Menzel C; Klein SA; Mose S; Grünwald F
Clin Nucl Med; 2003 Sep; 28(9):738-42. PubMed ID: 12972995
[TBL] [Abstract][Full Text] [Related]
18. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia.
Seitz U; Neumaier B; Glatting G; Kotzerke J; Bunjes D; Reske SN
Eur J Nucl Med; 1999 Oct; 26(10):1265-73. PubMed ID: 10541824
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
Zohren F; Czibere A; Bruns I; Fenk R; Schroeder T; Gräf T; Haas R; Kobbe G
Bone Marrow Transplant; 2009 Dec; 44(12):785-92. PubMed ID: 19430496
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
